According to our (Global Info Research) latest study, the global Adult Vaccines market size was valued at US$ 31115 million in 2025 and is forecast to a readjusted size of US$ 50536 million by 2032 with a CAGR of 7.1% during review period.
Adult vaccines are prophylactic human vaccines supplied for people aged 18 years and older to induce active immunity against infectious diseases. The scope includes routine vaccination, catch-up vaccination, boosters, maternal immunization and vaccines used for travel or occupational exposure. Products shared with younger age groups are included only to the extent attributable to adult use. Manufacturing involves antigen or nucleic-acid production, formulation, filling, quality control and distribution under product-specific storage conditions.
Key Findings
Global sales volume in 2025 was approximately 1.08 billion doses
The average ex-factory selling price in 2025 was approximately USD 28 per dose
Market Trends
Adult immunization is expanding beyond seasonal vaccination toward broader prevention across adulthood. Product development emphasizes age-specific protection, broader antigen coverage and more convenient delivery. Recombinant, conjugate and nucleic-acid platforms coexist with established manufacturing technologies, while vaccination services increasingly depend on accessible community channels and reliable immunization records.
Market Dynamics
Drivers
Population ageing increases the importance of preventing infections associated with substantial disease burden in older adults. Catch-up vaccination and management of occupational or travel-related exposure create additional demand. Funding, clinical recommendations and accessible delivery services help convert eligible populations into actual vaccination uptake.
Restraints
Adult vaccination often receives less systematic follow-up than childhood immunization. Out-of-pocket costs, limited awareness and fragmented records can restrict uptake. Product approval does not automatically establish broad reimbursement or public procurement, and demand can change when recommendations or purchasing arrangements are revised.
Opportunities
Community vaccination services, employer-supported programs and integration with chronic disease management can improve access. Opportunities also exist in markets introducing adult immunization funding and in products that address unmet prevention needs. Successful expansion requires alignment between eligible populations, financing and service capacity.
Challenges
Manufacturers face uncertain seasonal demand, inventory expiry and complex production lead times. Public confidence and communication affect uptake, while changes in policy can alter purchasing patterns. New products must demonstrate an appropriate benefit-risk profile and meet manufacturing, regulatory and post-marketing monitoring requirements.
Industry Chain Analysis
Upstream inputs include biological production materials, cell substrates, nucleic-acid inputs, adjuvants, excipients and pharmaceutical packaging. Manufacturers perform production, purification, formulation, filling and release testing, supported by specialized manufacturing partners where needed. Distribution connects manufacturers with public procurement agencies, healthcare providers and authorized pharmacy channels.
Segment Insights
Seasonal influenza supports recurring demand, while adult COVID vaccination remains sensitive to epidemiology and policy. Shingles, pneumococcal and respiratory syncytial virus vaccines contribute higher-priced product options, with adoption dependent on age eligibility, funding and delivery arrangements.
Adult human papillomavirus vaccination must be separated from adolescent programs. Hepatitis, tetanus-containing and travel vaccines serve catch-up or exposure-related needs. Dose counts should distinguish repeat annual vaccination from completion of a multi-dose primary course.
Downstream Market Opportunities
Public health services can expand adult coverage through organized procurement and outreach. General healthcare providers can integrate vaccination assessment into routine care. Occupational health and travel medicine services provide focused demand, while community delivery can reduce the time and access barriers associated with vaccination.
Regional Insights
North America and Europe offer established commercial channels for several adult vaccine categories, although uptake and reimbursement differ across countries. Asian markets combine large eligible populations with diverse financing arrangements and expanding domestic supply. Travel and exposure-related demand also varies with local disease patterns.
Manufacturing location should be distinguished from final consumption. International supply, licensing and public procurement connect production facilities with multiple markets, while local registration and access conditions determine where specific products can be sold.
Competitive Landscape Analysis
Competition varies substantially by vaccine category. Established international suppliers combine manufacturing capacity, clinical evidence and market access capabilities, while regional manufacturers provide additional options in influenza, hepatitis, pneumococcal, shingles and human papillomavirus vaccines. Comparisons should distinguish proprietary products from distribution agreements and avoid counting alliance revenue twice.
Report Scope
This report is a detailed and comprehensive analysis for global Adult Vaccines market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Adult Vaccines market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Adult Vaccines market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Adult Vaccines market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Adult Vaccines market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adult Vaccines
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adult Vaccines market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Merck & Co., Inc., Moderna, Inc., GSK plc, Sanofi, CSL Limited, Novavax, Inc., Bavarian Nordic A/S, Valneva SE, Takeda Pharmaceutical Company Limited, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Adult Vaccines market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Influenza Vaccines
COVID-19 Vaccines
Herpes Zoster Vaccines
Pneumococcal Vaccines
Respiratory Syncytial Virus Vaccines
Human Papillomavirus Vaccines
Other Adult Vaccines
Market segment by Technology Platform
Live Attenuated Vaccines
Inactivated Vaccines
Subunit, Polysaccharide, Conjugate and Toxoid Vaccines
Nucleic-acid and Non-replicating Viral Vector Vaccines
Market segment by Disease Coverage
Single-disease Vaccines
Multiple-disease Combination Vaccines
Market segment by Application
Public Health Services
General Healthcare Services
Occupational Health Services
Travel Medicine Services
Other
Major players covered
Pfizer Inc.
Merck & Co., Inc.
Moderna, Inc.
GSK plc
Sanofi
CSL Limited
Novavax, Inc.
Bavarian Nordic A/S
Valneva SE
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company, Limited
Meiji Seika Pharma Co., Ltd.
SK bioscience Co., Ltd.
SINOVAC Biotech Ltd.
Walvax Biotechnology Co., Ltd.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Shenzhen Kangtai Biological Products Co., Ltd.
Changchun BCHT Biotechnology Co.
Serum Institute of India Pvt. Ltd.
Bharat Biotech International Limited
Biological E. Limited
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Adult Vaccines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adult Vaccines, with price, sales quantity, revenue, and global market share of Adult Vaccines from 2021 to 2026.
Chapter 3, the Adult Vaccines competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adult Vaccines breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Adult Vaccines market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adult Vaccines.
Chapter 14 and 15, to describe Adult Vaccines sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Adult Vaccines. Industry analysis & Market Report on Adult Vaccines is a syndicated market report, published as Global Adult Vaccines Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Adult Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.